# Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

> **NCT00093821** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (actual)

## Conditions studied

- Childhood Chronic Myelogenous Leukemia
- Childhood Desmoplastic Small Round Cell Tumor
- Disseminated Neuroblastoma
- Metastatic Childhood Soft Tissue Sarcoma
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Metastatic Osteosarcoma
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma

## Interventions

- **DRUG:** tanespimycin
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00093821
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-08
- **Final completion:** —
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093821, "Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00093821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*